Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in Lung Neuroendocrine Tumors (SPINET)
NCT02683941Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Lung Neuroendocrine Tumor comparing Lanreotide with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 33 months. Started Mar 2017; status: terminated.
02
Drugs
lanreotide
03
Conditions
Lung Neuroendocrine Tumor
Beyond the preview
Go deeper on NCT02683941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683941.